Understand the source comparison
Peptides for Liver Health Detox — Clinical vs Research Use
BPC-157 VEGF modulation, NF- B inhibition, stellate cell suppression 200–500 mcg SQ daily (human equivalent from animal models) Preclinical only. No Phase III human trials Strongest evidence for fibrosis reduction in CCl4 and alcohol injury models; mechanism p
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF modulation, NF-κB inhibition, stellate cell suppression
- 200–500 mcg SQ daily (human equivalent from animal models)
- Preclinical only. No Phase III human trials
- Strongest evidence for fibrosis reduction in CCl4 and alcohol injury models; mechanism plausible for NAFLD support
- Thymosin Beta-4 (TB-500)
- Actin stabilization, hepatocyte migration, TGF-β1 downregulation
- 2–5 mg SQ twice weekly (research protocols)
- Preclinical + Phase I safety data in wound healing
- Well-tolerated in human trials for other indications; hepatoprotection extrapolated from tissue repair studies
- Epitalon
- Mitochondrial protection, telomerase activation, lipid peroxidation reduction
- 1–10 mcg/kg daily (animal research)
- Preclinical only. Limited human pharmacokinetic data
- Mechanism targets root cause of metabolic liver stress; dosing in humans not standardized
- Reduced Glutathione
- Direct Phase II substrate, ROS scavenging
- 500–1000 mg oral (bioavailability <10%) or 600 mg IV
- Multiple RCTs for acetaminophen overdose; mixed data for chronic liver disease
- Oral bioavailability severely limits efficacy; IV form bypasses gut degradation but requires clinical administration